Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes.
Metabasis Therapeutics Inc (formerly Gensia Sicor Inc, which became SICOR Inc), in collaboration with Daiichi Sankyo Co Ltd (formerly Sankyo Co Ltd) is developing the fructose-1,6-bisphosphatase inhibitor managlinat dialanetil, a low-molecular weight purine nucleotide analog that inhibits gluconeogenesis, for the potential treatment of type 2 diabetes. Phase II clinical trials of the compound are underway in Europe and the US.